Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody in the United States

CAMBRIDGE,Mass.,ROTTERDAM and SUZHOU,China,Oct. 20,2022 --Harbour BioMed ("HBM",HKEX: 02142) announced that,it has successfully completed the dosing of first patient in the global phase I trial of B7H4x4-1BB bispecific antibody HBM7008 in the United States. This study will evaluate the safety,tolerability,pharmacokinetics,pharmacodynamics,and preliminary anti-tumor activity of HBM7008 in patients with solid tumors.

HBM7008 is generated from Harbour BioMed's unique and innovative HBICE®platform,leveraging the advantages of the HCAb and H2L2 platforms. It targets Tumor-Associated Antigen (B7H4),mediated crosslinking T cell activation through 4-1BB. B7H4 is overexpressed on a variety of solid malignancies,including breast,ovarian,endometrial,and non-small cell lung cancers. With its crosslinking dependent specificity on tumors and potent immune modulation activity,HBM7008 has shown excellent safety profile with strong anti-tumor efficacy in the pre-clinical study,including completed response observed in the mouse tumor model.

"We are pleased to have completed the first patient dosing of B7H4x4-1BB in the U.S.,marking another milestone to lead next-gen immuno-oncology therapeutics innovation in global market. Following our global innovation and development strategy,Harbour BioMed will advance the global clinical development project of HBM7008 at full speed to provide a novel,effective and safe treatment for patients." said Dr. Jingsong Wang,Founder,Chairman and CEO of Harbour BioMed.

About HBM7008

HBM7008 is a bispecific antibody targeting Tumor Associated Antigen B7H4x4-1BB that not only displays high potency in the T cell co-stimulation and tumor growth inhibition,and potentially may also translate to better safety due to its strict dependency of TAA-mediated crosslinking T cell activation. HBM7008 is one of the fully human bispecific antibodies developed from the HBICE® platform of the Company. It is the only bispecific antibody against these two targets globally. Its unique specificity on tumors and immune modulation activity makes it a promising therapeutic in PD-L1 negative or PD-1/PD-L1 resistant patients. It also has the potential to avoid 4-1BB liver toxicity risk observed in other products with the benefit of its innovative biology mechanisms and bispecific design.

About Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery,development and commercialization of novel antibody therapeutics focusing on immunology and oncology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability,collaborations with co-discovery and co-development partners and select acquisitions.

The Company's proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format,as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies,the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice®,HBICE® with single B cell cloning platform,our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.

View original content to download multimedia:https://www.prnewswire.com/news-releases/harbour-biomed-announces-dosing-of-first-patient-in-phase-i-trial-of-b7h4x4-1bb-bispecific-antibody-in-the-united-states-301654592.html